EDINBURGH, Scotland, Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox.Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of Surrey, Unit ...

TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could have additional applications across cell therapy for donor/patient matching EDINBURGH, Scotland, Oct. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer an ...

Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland, Sept. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial. Guys and St. Thomas is a ...

EDINBURGH, Scotland, Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer Bryan Kobel has been invited to present at the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York City. Mr. Kobel plans to provide insight into the company's clinical tria ...

No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE P ...

EDINBURGH, Scotland, Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) ce ...

EDINBURGH, Scotland, Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the H.C. Wainwright 26th Annual Global Investment Conference from September 9–11, 2024 in New York City. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison A ...

Core Insights - TC BioPharm has successfully dosed a total of 6 patients in the ACHIEVE Phase 2b trial, with 5 new patients receiving their first dose at a higher dose level [1][2] - The trial involves administering up to 1 billion gamma delta T cells over four doses, with each 5mL dose containing up to 230 million cells [2] - The company has reported strong patient recruitment and retention rates, indicating significant clinician interest in TCB008 as a monotherapy for blood cancers [3] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment, specifically acute myeloid leukemia [5][6] - The company is recognized as a leader in this field and is the first to conduct Phase II/pivotal clinical studies in oncology using its proprietary allogeneic CryoTC technology [6] - Gamma-delta T cells are immune cells that can differentiate between healthy and diseased tissue, embodying properties of both the innate and adaptive immune systems [5]

Core Viewpoint - TC BioPharm has successfully closed a public offering, raising $6 million to support its clinical trials and operational expenses [1][2]. Group 1: Offering Details - The public offering was upsized to 6,000,000 American Depository Shares (ADSs) at a price of $1 per ADS, along with Series H warrants [1]. - The Series H warrants have an exercise price of £0.76 per ADS and will expire one year from issuance [1]. - Each ADS represents 200 ordinary shares of the company [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for a clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness, and ongoing operating expenses [2]. Group 3: Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies for cancer treatment, with a focus on acute myeloid leukemia [6]. - The company is recognized as a leader in developing gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [6]. - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, utilizing proprietary allogeneic CryoTC technology [6].

EDINBURGH, Scotland, Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta cells for the treatment of cancer and viral indications. The Company intends to proceed with the patent process in specific Eu ...